Immune Netw.  2002 Mar;2(1):49-52. 10.4110/in.2002.2.1.49.

Autologous Peripheral Blood Stem Cell Transplantation Using G-CSF Combined Conditioning in AML Patients

• Kim BS
• Kook H
• Hwang TJ
• Choi CW
• Kim JS

• KMID: 1571392
• DOI: http://doi.org/10.4110/in.2002.2.1.49

Abstract

BACKGROUND: The possibility that G-CSF recruits leukemic cells from the G0 to S phase, which may lead to a greater susceptibility to cytotoxic drugs, such as ara-C, has been presented in Harada's study.
METHODS
In this study, we referred to the protocol of Harada et al 1 to try G-CSF combined marrow-ablative chemotherapy and autologous PBSCT, for the treatment of AML patients in CR1 status. Between January 1997 and March 1998, six AML patients (3: children, 3: adults) in CR1 status were autografted and followed up to 3 years.
RESULTS
The major regimen related toxicity was composed of mucositis and diarrhea without death. The time of ANC recovery to 500/L and 1,000/L was 11~48 and 16~81 days, respectively. The mean time of platelet recovery to 20,000/L and 50,000/L was 21~233 and 35~370 days, respectively. The platelet recovery time to 50,000/L was markedly prolonged for more than 100 days in four patients (66.7%). Moreover, four patients (66.7%) experienced a relapse of leukemia after transplantation, with a mean interval of 147.5 days after PBSCT. Two patients were in CR status for 53 and 51 months after PBSCT, respectively.
CONCLUSION
The G-CSF combined marrow-ablative chemotherapy and autologous PBSCT resulted in a markedly delayed platelet recovery and no advantages for decreasing the relapse rate of AML. But, further studies will be warranted.

Keyword

G-CSF combined myeloablative chemotherapy; autologous PBSCT

MeSH Terms

Autografts
Blood Platelets
Child
Cytarabine
Diarrhea
Drug Therapy
Granulocyte Colony-Stimulating Factor*
Humans
Leukemia
Mucositis
Peripheral Blood Stem Cell Transplantation*
Recurrence
S Phase
Cytarabine
Granulocyte Colony-Stimulating Factor